114 An Assessment of QTc Effects With SPN-812 (Extended-Release Viloxazine) in Healthy Adults

Abstract

Study Objective: SPN‐812 (extended‐release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) under investigation as a treatment for attention‐deficit/hyperactivity disorder (ADHD). One concern for any new drug is prolongation of the QT interval, which is associated with increased risk for potentially very harmful ventricular cardiac arrhythmias such as torsades de pointes (TdP). The objective ofthis study wastoassess the effectsofSPN‐812atasupratherapeutic dose (1800mgonce daily [QD]) on cardiac repolarization (QTc) in healthy adults. METHOD: This study was a Phase 1, double‐blind (except for the positive control moxifloxacin), randomized, 3‐period, 6‐sequence crossover design in healthy adult male and female subjects evaluating the electrocardio‐graphic effects of SPN‐812. Subjects were randomized to receive a sequence of all 3 treatments ‐ placebo, 400 mg moxifloxacin (positive control), and 1800 mg SPN‐812 (supratherapeutic dose). Treatment was given for 2 consecutive days (separated by a washout of at least 4 days). The primary endpoint was based on concentration‐QTc effect modeling, evaluating the relationship between plasma concentrations of SPN‐812 and its metabolite 5‐hydroxyviloxazine glucuronide (5‐HVLX‐gluc) with the placebo‐adjusted change from baseline in QTcI, ΔΔQTcI (QT interval corrected for HR based on the individual‐specific QT interval correction method). Secondary endpoints included time point change from baseline in QTcI, QTcF, HR, PR, and QRS; evaluation of the relationship between the plasma concentration of vilox‐azine and 5‐HVLX‐gluc and the placebo‐adjusted change from baseline in HR, PR, QRS, and QTcF; evaluation of the relationship between the plasma concentration of moxifloxacin and ΔΔQTcI to demonstrate assay sensitivity; and changes in ECG morphology. Safety endpoints included assessment of adverse events and other parameters. RESULTS: The relationship between ΔΔQTcI and viloxa‐zine plasma concentration demonstrated a negative slope (p=0.0012). Predicted mean ΔΔQTcI (2‐sided 90% CI) for SPN‐812 was ‐9.7 ms (‐11.3, ‐8.1) at the mean Cmax of 12.4 μg/mL. The relationship of 5‐HVLX‐gluc and ΔΔQTcI similarly demonstrated a predicted negative slope (p=0.0007) with a predicted mean ΔΔQTcI (2‐sided 90% CI) of ‐9.2 ms (‐10.8, ‐7.8) at the mean Cmax of 10.0 μg/mL. Assay sensitivity was confirmed. Concentration‐effect modeling demonstrated no relationship between plasma concentrations of viloxazine and 5‐HVLX‐gluc and other ECG parameters. The secondary time point analyses demonstratedno effect of SPN‐812 on QTcI or other ECG intervals. SPN‐812 produced no changes in ECG T wave or U wave morphology. CONCLUSIONS: Data from this Phase 1 thorough QT study demonstrate that a supratherapeutic dose of SPN‐812, 1800 mg QD, has no effect on cardiac repo‐larization or other ECG parameters, and is thus not associated with a risk for cardiac arrhythmias such as TdP.